Is AVTX or VKTX more profitable?

Avalo Therapeutics' return on equity of -58.03% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Viking Therapeutics N/A -94.56% -82.75%

Does the media prefer AVTX or VKTX?

In the previous week, Viking Therapeutics had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 13 mentions for Viking Therapeutics and 10 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Viking Therapeutics' score of 0.58 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher earnings & valuation, AVTX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalo Therapeutics $60K 14,462.22 -$78.26M -$4.37 N/A Telix Pharmaceuticals $803.79M 4.98 -$7.12M N/A N/A

Is AVTX or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Telix Pharmaceuticals N/A N/A N/A

Does the media prefer AVTX or TLX?

In the previous week, Telix Pharmaceuticals had 7 more articles in the media than Avalo Therapeutics. MarketBeat recorded 17 mentions for Telix Pharmaceuticals and 10 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Telix Pharmaceuticals' score of 0.17 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 3 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IOVA or AVTX?

In the previous week, Avalo Therapeutics had 4 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.40 beat Avalo Therapeutics' score of 0.83 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVTX or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media refer more to AVTX or AMLX?

In the previous week, Avalo Therapeutics had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Avalo Therapeutics and 9 mentions for Amylyx Pharmaceuticals. Avalo Therapeutics' average media sentiment score of 0.83 beat Amylyx Pharmaceuticals' score of 0.66 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNGX or AVTX more profitable?

Tango Therapeutics' return on equity of -25.75% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -25.75% -23.36% Avalo Therapeutics N/A -58.03% -48.22%

Does the media favor TNGX or AVTX?

In the previous week, Avalo Therapeutics had 7 more articles in the media than Tango Therapeutics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 3 mentions for Tango Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Tango Therapeutics' score of 0.69 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Avalo Therapeutics (AVTX) Competitors

$16.18 +0.06 (+0.37%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$16.18 0.00 (0.00%)

As of 09/14/2026 07:30 PM Eastern

Compare

AVTX vs. VKTX, TLX, IOVA, AMLX, and TNGX

Should you buy Avalo Therapeutics stock or one of its competitors? Avalo Therapeutics's main competitors and comparable companies include Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), and Tango Therapeutics (TNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avalo Therapeutics compare to Viking Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Avalo Therapeutics currently has a consensus target price of $45.10, indicating a potential upside of 178.74%. Viking Therapeutics has a consensus target price of $96.63, indicating a potential upside of 206.45%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Viking Therapeutics had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 13 mentions for Viking Therapeutics and 10 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Viking Therapeutics' score of 0.58 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Avalo Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Avalo Therapeutics' return on equity of -58.03% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Viking Therapeutics	N/A	-94.56%	-82.75%

Avalo Therapeutics has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	14,462.22	-$78.26M	-$4.37	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Summary

Avalo Therapeutics beats Viking Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Avalo Therapeutics (NASDAQ:AVTX) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Telix Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	14,462.22	-$78.26M	-$4.37	N/A
Telix Pharmaceuticals	$803.79M	4.98	-$7.12M	N/A	N/A

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

Avalo Therapeutics currently has a consensus target price of $45.10, suggesting a potential upside of 178.74%. Telix Pharmaceuticals has a consensus target price of $20.40, suggesting a potential upside of 73.17%. Given Avalo Therapeutics' higher possible upside, equities analysts plainly believe Avalo Therapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Telix Pharmaceuticals had 7 more articles in the media than Avalo Therapeutics. MarketBeat recorded 17 mentions for Telix Pharmaceuticals and 10 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Telix Pharmaceuticals' score of 0.17 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalo Therapeutics and Telix Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Avalo Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Avalo Therapeutics (NASDAQ:AVTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Avalo Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Avalo Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	15.92	-$390.98M	-$0.73	N/A
Avalo Therapeutics	$60K	14,462.22	-$78.26M	-$4.37	N/A

Iovance Biotherapeutics currently has a consensus price target of $8.89, indicating a potential downside of 4.01%. Avalo Therapeutics has a consensus price target of $45.10, indicating a potential upside of 178.74%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Avalo Therapeutics had 4 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.40 beat Avalo Therapeutics' score of 0.83 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Iovance Biotherapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Avalo Therapeutics beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Amylyx Pharmaceuticals?

Avalo Therapeutics (NASDAQ:AVTX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

In the previous week, Avalo Therapeutics had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Avalo Therapeutics and 9 mentions for Amylyx Pharmaceuticals. Avalo Therapeutics' average media sentiment score of 0.83 beat Amylyx Pharmaceuticals' score of 0.66 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics currently has a consensus target price of $45.10, suggesting a potential upside of 178.74%. Amylyx Pharmaceuticals has a consensus target price of $36.50, suggesting a potential upside of 8.50%. Given Avalo Therapeutics' higher probable upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Avalo Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

Amylyx Pharmaceuticals' return on equity of -52.92% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Avalo Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	14,462.22	-$78.26M	-$4.37	N/A
Amylyx Pharmaceuticals	$87.37M	42.90	-$144.74M	-$1.43	N/A

Summary

Avalo Therapeutics beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Avalo Therapeutics (NASDAQ:AVTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tango Therapeutics' return on equity of -25.75% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Avalo Therapeutics has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	66.33	-$101.59M	-$0.85	N/A
Avalo Therapeutics	$60K	14,462.22	-$78.26M	-$4.37	N/A

Tango Therapeutics currently has a consensus price target of $43.46, indicating a potential upside of 77.10%. Avalo Therapeutics has a consensus price target of $45.10, indicating a potential upside of 178.74%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, Avalo Therapeutics had 7 more articles in the media than Tango Therapeutics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 3 mentions for Tango Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Tango Therapeutics' score of 0.69 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Avalo Therapeutics beats Tango Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTX vs. The Competition

Export

Metric	Avalo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$864.52M	$3.86B	$7.15B	$13.98B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-3.70	14.33	273.28	25.37
Price / Sales	14,462.22	1,345.75	615.17	75.12
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	3.60	15.26	10.43	6.24
Net Income	-$78.26M	-$22.78M	$3.49B	$358.08M
7 Day Performance	-17.91%	-0.79%	-1.15%	-0.70%
1 Month Performance	-17.41%	2.12%	0.56%	-2.76%
1 Year Performance	59.57%	41.90%	20.17%	6.72%

Avalo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTX Avalo Therapeutics	3.4522 of 5 stars	$16.18 +0.4%	$45.10 +178.7%	+51.9%	$864.52M	$60K	N/A	33	Analyst Downgrade
VKTX Viking Therapeutics	2.9086 of 5 stars	$33.68 -3.4%	$96.63 +186.9%	+27.1%	$4.07B	N/A	N/A	20
TLX Telix Pharmaceuticals	3.6055 of 5 stars	$11.98 +0.3%	$20.40 +70.3%	+27.9%	$4.06B	$803.79M	N/A	1,184	Trending News Analyst Forecast High Trading Volume
IOVA Iovance Biotherapeutics	1.6488 of 5 stars	$8.70 -1.0%	$8.89 +2.2%	+307.9%	$3.98B	$263.50M	N/A	500	Positive News
AMLX Amylyx Pharmaceuticals	3.1814 of 5 stars	$33.88 -0.6%	$36.50 +7.7%	+188.8%	$3.80B	$87.37M	N/A	200	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTX) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalo Therapeutics (AVTX) Competitors

AVTX vs. VKTX, TLX, IOVA, AMLX, and TNGX

How does Avalo Therapeutics compare to Viking Therapeutics?

Summary

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Avalo Therapeutics compare to Iovance Biotherapeutics?

Summary

How does Avalo Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does Avalo Therapeutics compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalo Therapeutics (AVTX) Competitors

AVTX vs. VKTX, TLX, IOVA, AMLX, and TNGX

How does Avalo Therapeutics compare to Viking Therapeutics?

Do analysts prefer AVTX or VKTX?

Does the media prefer AVTX or VKTX?

Which has more risk and volatility, AVTX or VKTX?

Do institutionals and insiders believe in AVTX or VKTX?

Is AVTX or VKTX more profitable?

Which has stronger earnings and valuation, AVTX or VKTX?

Summary

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Is AVTX or TLX more profitable?

Which has higher earnings & valuation, AVTX or TLX?

Do institutionals & insiders hold more shares of AVTX or TLX?

Which has more risk & volatility, AVTX or TLX?

Do analysts rate AVTX or TLX?

Does the media prefer AVTX or TLX?

Summary

How does Avalo Therapeutics compare to Iovance Biotherapeutics?

Is IOVA or AVTX more profitable?

Which has better valuation & earnings, IOVA or AVTX?

Do analysts rate IOVA or AVTX?

Do institutionals & insiders have more ownership in IOVA or AVTX?

Does the media favor IOVA or AVTX?

Which has more volatility and risk, IOVA or AVTX?

Summary

How does Avalo Therapeutics compare to Amylyx Pharmaceuticals?

Does the media refer more to AVTX or AMLX?

Do analysts prefer AVTX or AMLX?

Do institutionals & insiders have more ownership in AVTX or AMLX?

Which has more volatility & risk, AVTX or AMLX?

Is AVTX or AMLX more profitable?

Which has better valuation and earnings, AVTX or AMLX?

Summary

How does Avalo Therapeutics compare to Tango Therapeutics?

Which has more risk and volatility, TNGX or AVTX?

Do insiders & institutionals have more ownership in TNGX or AVTX?

Is TNGX or AVTX more profitable?

Which has higher valuation & earnings, TNGX or AVTX?

Do analysts prefer TNGX or AVTX?

Does the media favor TNGX or AVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools